| Year |
Citation |
Score |
| 2021 |
Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, ... ... James CD, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine. 13. PMID 33692132 DOI: 10.1126/scitranslmed.abb3945 |
0.367 |
|
| 2019 |
Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C, Carpentier A, Desseaux C, Canney M, Muzzio M, Stupp R, et al. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31831565 DOI: 10.1158/1078-0432.Ccr-19-2182 |
0.323 |
|
| 2019 |
XI G, Mahenthiran A, Best B, Nayak S, Smith C, McClendon M, Mania-Farnell B, Kessler J, James C, Stupp S, Tomita T. EXTH-18. PEPTIDE NANO-STRUCTURES ENHANCE PEDIATRIC BRAIN TUMOR CHEMOTHERAPEUTIC EFFICACY Neuro-Oncology. 21: vi86-vi86. DOI: 10.1093/Neuonc/Noz175.352 |
0.337 |
|
| 2017 |
Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Translational Oncology. 10: 669-678. PMID 28672195 DOI: 10.1016/J.Tranon.2017.06.003 |
0.334 |
|
| 2017 |
Sita TL, Kouri FM, Hurley LA, Merkel TJ, Chalastanis A, May JL, Ghelfi ST, Cole LE, Cayton TC, Barnaby SN, Sprangers AJ, Savalia N, James CD, Lee A, Mirkin CA, et al. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proceedings of the National Academy of Sciences of the United States of America. PMID 28373576 DOI: 10.1073/Pnas.1702736114 |
0.307 |
|
| 2017 |
Wainwright DA, Horbinski CM, Hashizume R, James CD. Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28321824 DOI: 10.1007/S13311-017-0523-1 |
0.331 |
|
| 2016 |
Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. PMID 27713119 DOI: 10.18632/Oncotarget.12419 |
0.313 |
|
| 2016 |
Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology. PMID 26782702 DOI: 10.1007/S11060-015-2024-6 |
0.407 |
|
| 2015 |
Lu Y, Chang Y, Cheng L, Wei K, Ozawa T, Kim J, Waldman T, James CD. MTR-07GLIOBLASTOMA ADAPTATION TO SUSTAINED cdk4/6 INHIBITION INVOLVES SUPPRESSION OF Rb EXPRESSION THROUGH HISTONE H3K4 MODIFICATION Neuro-Oncology. 17: v125.3-v125. DOI: 10.1093/Neuonc/Nov219.07 |
0.307 |
|
| 2015 |
Ugolkov A, Bondarenko G, Gaisina I, Dubrovskyi O, Yemelyanov A, James C, Chandler J, O'Halloran T, Kozikowski A, Raizer J, Mazar A. ATPS-91GSK-3 INHIBITOR 9-ING-41 ENHANCES GENOTOXIC THERAPY OF GBM LEADING TO CURE FROM INTRACRANIAL BRAIN TUMOR Neuro-Oncology. 17: v38.3-v38. DOI: 10.1093/Neuonc/Nov204.91 |
0.372 |
|
| 2015 |
Olow AK, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Berger MS, Gupta N, James CD, Haas-Kogan DA. TR-08 * TARGETED COMBINATORIAL APPROACH FOR TREATMENT OF PEDIATRIC LOW GRADE GLIOMAS IN THE CONTEXT OF BRAFV600E AND KIAA1549:BRAF MUTATIONS Neuro-Oncology. 17: iii38-iii38. DOI: 10.1093/Neuonc/Nov061.153 |
0.305 |
|
| 2014 |
Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular Cancer Therapeutics. 13: 2919-29. PMID 25313012 DOI: 10.1158/1535-7163.Mct-14-0306 |
0.31 |
|
| 2014 |
Persson AI, Ilkhanizadeh S, Miroshnikova YA, Frantz A, Lakins JN, James CD, McKnight TR, Berger MS, Bergers G, Weiss WA, Weaver VM. HIGH INTERSTITIAL FLUID PRESSURE REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA Neuro-Oncology. 16: iii32-iii32. DOI: 10.1093/Neuonc/Nou208.37 |
0.317 |
|
| 2013 |
Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS. Cidofovir: a novel antitumor agent for glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6473-83. PMID 24170543 DOI: 10.1158/1078-0432.CCR-13-1121 |
0.329 |
|
| 2013 |
Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (London, England). 8: 1913-25. PMID 23631502 DOI: 10.2217/Nnm.12.209 |
0.693 |
|
| 2013 |
Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-Oncology. 15: 189-97. PMID 23262509 DOI: 10.1093/Neuonc/Nos305 |
0.424 |
|
| 2013 |
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... James CD, ... ... James CD, ... ... James CD, ... ... James CD, ... ... James CD, ... ... James CD, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176 |
0.684 |
|
| 2012 |
Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America. 109: 8710-5. PMID 22586120 DOI: 10.1073/Pnas.1117255109 |
0.447 |
|
| 2012 |
Toussaint LG, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Molecular Cancer. 11: 32. PMID 22583806 DOI: 10.1186/1476-4598-11-32 |
0.302 |
|
| 2012 |
Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Advanced Drug Delivery Reviews. 64: 590-7. PMID 22306489 DOI: 10.1016/J.Addr.2012.01.004 |
0.72 |
|
| 2012 |
Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. Journal of Neuro-Oncology. 108: 29-35. PMID 22231932 DOI: 10.1007/s11060-011-0796-x |
0.567 |
|
| 2012 |
Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 59: 193-201. PMID 21807103 DOI: 10.1016/j.neuroimage.2011.07.034 |
0.323 |
|
| 2011 |
Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro-Oncology. 13: 1288-95. PMID 21954443 DOI: 10.1093/Neuonc/Nor139 |
0.724 |
|
| 2011 |
Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology. 13: 384-92. PMID 21317208 DOI: 10.1093/Neuonc/Noq193 |
0.315 |
|
| 2011 |
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... James CD, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158 |
0.69 |
|
| 2010 |
Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. Journal of Visualized Experiments : Jove. PMID 20736920 DOI: 10.3791/1992 |
0.703 |
|
| 2010 |
Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. Journal of Visualized Experiments : Jove. PMID 20644517 DOI: 10.3791/1986 |
0.336 |
|
| 2010 |
Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Molecular Cancer Therapeutics. 9: 2131-41. PMID 20587664 DOI: 10.1158/1535-7163.MCT-09-1059 |
0.303 |
|
| 2010 |
Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD, VandenBerg SR. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-Oncology. 12: 366-76. PMID 20308314 DOI: 10.1093/Neuonc/Nop033 |
0.347 |
|
| 2010 |
Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N. A human brainstem glioma xenograft model enabled for bioluminescence imaging. Journal of Neuro-Oncology. 96: 151-9. PMID 19585223 DOI: 10.1007/s11060-009-9954-9 |
0.317 |
|
| 2008 |
Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A. An orthotopic skull base model of malignant meningioma. Brain Pathology (Zurich, Switzerland). 18: 172-9. PMID 18093250 DOI: 10.1111/J.1750-3639.2007.00109.X |
0.333 |
|
| 2007 |
Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. Journal of Neurosurgery. 107: 610-6. PMID 17886562 DOI: 10.3171/JNS-07/09/0610 |
0.349 |
|
| 2005 |
Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology. 7: 164-76. PMID 15831234 DOI: 10.1215/S1152851704000821 |
0.306 |
|
| 2004 |
Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Seminars in Oncology. 31: 595-604. PMID 15497113 DOI: 10.1053/j.seminoncol.2004.07.002 |
0.334 |
|
| 2003 |
Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Frontiers in Bioscience : a Journal and Virtual Library. 8: e270-80. PMID 12700121 |
0.331 |
|
| Show low-probability matches. |